EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health

Sukrit Srivastava iD, Sonia Verma, Mohit Kamthania, Ajay Kumar Saxena, Kailash C Pandey, Veena Pande, Michael Kolbe

PLOS ONE · 15.03.2023 · 18 (3) · e0282580

DOI: 10.1371/journal.pone.0282580 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 15.03.2023. Verfasst von Sukrit Srivastava und 6 weiteren Autor:innen. Beteiligte Einrichtung: Infection Biology Group, Indian Foundation for Fundamental Research Trust, RaeBareli, India. Hauptthemen laut MEDLINE: beta-Defensins, Henipavirus Infections, Viral Vaccines. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Helmholtz-Centre for Infection Research, pre4D, Indian Foundation for Fundamental Research Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nipah virus (NiV) is an emerging zoonotic virus that caused several serious outbreaks in the south asian region with high mortality rates ranging from 40 to 90% since 2001. NiV infection causes lethal encephalitis and respiratory disease with the symptom of endothelial cell-cell fusion. No specific and effective vaccine has yet been reported against NiV. To address the urgent need for a specific and effective vaccine against NiV infection, in the present study, we have designed two Multi-Epitope Vaccines (MEVs) composed of 33 Cytotoxic T lymphocyte (CTL) epitopes and 38 Helper T lymphocyte (HTL) epitopes. Out of those CTL and HTL combined 71 epitopes, 61 novel epitopes targeting nine different NiV proteins were not used before for vaccine design. Codon optimization for the cDNA of both the designed MEVs might ensure high expression potential in the human cell line as stable proteins. Both MEVs carry potential B cell linear epitope overlapping regions, B cell discontinuous epitopes as well as IFN-γ inducing epitopes. Additional criteria such as sequence consensus amongst CTL, HTL and B Cell epitopes was implemented for the design of final constructs constituting MEVs. Hence, the designed MEVs carry the potential to elicit cell-mediated as well as humoral immune response. Selected overlapping CTL and HTL epitopes were validated for their stable molecular interactions with HLA class I and II alleles and in case of CTL epitopes with human Transporter Associated with antigen Processing (TAP) cavity. The structure based epitope cross validation for interaction with TAP cavity was used as another criteria choosing final epitopes for NiV MEVs. Finally, human Beta-defensin 2 and Beta-defensin 3 were used as adjuvants to enhance the immune response of both the MEVs. Molecular dynamics simulation studies of MEVs-TLR3 ectodomain (Human Toll-Like Receptor 3) complex indicated the stable molecular interaction. We conclude that the MEVs designed and in silico validated here could be highly potential vaccine candidates to combat NiV infections, with great effectiveness, high specificity and large human population coverage worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

beta-DefensinsHenipavirus InfectionsViral VaccinesHumansComputational BiologyEpitopes, B-LymphocyteEpitopes, T-LymphocyteMolecular Docking SimulationToll-Like Receptor 3Vaccines, SubunitHLA AntigensRNA-Binding ProteinsNucleocytoplasmic Transport Proteins

Substanzen

beta-DefensinsEpitopes, B-LymphocyteEpitopes, T-LymphocyteToll-Like Receptor 3Vaccines, SubunitViral VaccinesHLA AntigensTLR3 protein, humanNXF1 protein, humanRNA-Binding Proteins

Autor:innen und Institutionen

  • Infection Biology Group, Indian Foundation for Fundamental Research Trust, RaeBareli, India.
  • Department for Structural Infection Biology, Centre for Structural Systems Biology (CSSB) & Helmholtz-Centre for Infection Research, Hamburg, Germany.
  • Protein Biochemistry & Engineering Lab, Parasite-Host Biology Group, ICMR-National Institute of Malaria Research, New Delhi, India.
  • Molecular Medicine Lab., School of Life Science, Jawaharlal Nehru University, New Delhi, India.
  • Kumaun University, Bheemtal, Nainital, Uttarakhand, India.
  • Faculty of Mathematics, Informatics and Natural Sciences, University of Hamburg, Hamburg, Germany.

ORCID-Profile: Sukrit Srivastava

Förderung

  • Helmholtz-Centre for Infection Research
  • pre4D
  • Indian Foundation for Fundamental Research Trust

Zitieren

APA

Srivastava, S., Verma, S., Kamthania, M., Saxena, A. K., Pandey, K. C., Pande, V., & Kolbe, M. (2023). Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health. PLOS ONE, 18(3), e0282580. https://doi.org/10.1371/journal.pone.0282580

Vancouver

Srivastava S, Verma S, Kamthania M, Saxena AK, Pandey KC, Pande V, et al. Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health. PLOS ONE. 2023;18(3):e0282580. doi:10.1371/journal.pone.0282580

BibTeX
@article{Srivastava2023,
  author = {Srivastava, Sukrit and Verma, Sonia and Kamthania, Mohit and Saxena, Ajay Kumar and Pandey, Kailash C and Pande, Veena and Kolbe, Michael},
  title = {Exploring the structural basis to develop efficient multi-epitope vaccines displaying interaction with HLA and TAP and TLR3 molecules to prevent NIPAH infection, a global threat to human health},
  journal = {PLOS ONE},
  year = {2023},
  volume = {18},
  number = {3},
  pages = {e0282580},
  doi = {10.1371/journal.pone.0282580}
}
Kostenlos starten →